vTv Therapeutics Inc. (NASDAQ:VTVT) is one of them Most Promising Microcap Stock According to Analysts. On February 2, vTv Therapeutics expanded its partnership with Newswara Biopharma Inc., turning a regional agreement into a global collaboration for the development of HPP737. Under the amended terms, Newswara acquires exclusive worldwide rights to develop and commercialize this novel PDE4 inhibitor. In return, vTv Therapeutics will receive an additional $115 million in potential future development and an immediate payment of $20 million in sales milestones, plus royalties on net sales.
HPP737 is a selective oral therapy designed to treat inflammation-mediated diseases, such as psoriasis, by inhibiting interleukin-23 and tumor necrosis factor alpha. While traditional PDE4 inhibitors are often limited by gastrointestinal side effects such as nausea and vomiting, preliminary clinical data suggest that HPP737 is well tolerated and may prevent these common side effects. This differentiated profile positions the drug as a potentially best-in-class treatment in a historically limited therapeutic target.
The $20 million acquisition strengthens vTv’s balance sheet as the company focuses on its primary clinical asset, cadisegliatin. Currently in phase 3 trials, cadisegliatin is a liver-selective glucokinase activator being investigated as first-line oral adjunctive therapy for type 1 diabetes. Leveraging NewsVara’s development capabilities for HPP737, vTv Therapeutics Inc. ( NASDAQ:VTVT ) can prioritize its late-stage diabetes pipeline while maintaining a diversified source of long-term value through global milestones and concessions.
vTv Therapeutics Inc. ( NASDAQ:VTVT ) is a late-stage biopharmaceutical company developing oral small molecule drug candidates aimed at treating people living with diabetes and other chronic diseases.
While we recognize VTVT’s potential as an investment, we believe some AI stocks offer higher potential and lower risk. If you’re looking for the most undervalued AI stocks that stand to benefit significantly from Trump-era tariffs and the offshore trend, check out our free report Best short-term AI stocks.
Read more: The 40 Most Popular Stocks Among Hedge Funds in 2026 and the 11 Best Small-Cap Tech Stocks with the Highest Potential.
Disclosure: None. Follow the inside port on Google News.
